- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04322396
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 (ProPAC-COVID)
Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
In the ongoing coronavirus pandemic, COVID-19, that arose in Wuhan China, there is still sparse data in the course, risk of various complications, and in particular how patients who are hospitalized are best treated to ensure high survival and short hospitalization. Despite the rapid spread of the disease globally, there is no solid data yet to recommend any specific treatments, which is why symptomatic, organ supportive therapy including respiratory therapy in acute pulmonary failure is recommended. There has been reported a high incidence of bacterial super-infections in patients with COVID-19. Patients with COVID-19 also have a higher risk of dying because of septic shock. Thus, there is an urgent need for treatment that can improve the patient's chance of the shortest hospitalization possible, and treatment that can lower the risk of secondary infection and death.
This is a randomized, placebo-controlled, double-blinded multi-center trial evaluating the effect of azithromycin and hydroxychloroquine treatment in patients with COVID-19 during hospitalization. The aim of the study is to investigate whether the treatment can shorten hospitalization, reduce the risk of non-invasive ventilation, admittance to Intensive Care Units and death.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Aalborg, Danmark
- Aalborg Sygehus
-
Copenhagen, Danmark
- Bispebjerg Hospital
-
Copenhagen, Danmark
- Hvidovre Hospital
-
Copenhagen, Danmark
- Herlev-Gentofte Hospital
-
Hillerød, Danmark
- Nordsjællands Hospital
-
Odense, Danmark
- Odense Universitetshospital
-
Roskilde, Danmark
- Roskilde Sygehus
-
Slagelse, Danmark
- Slagelse Sygehus
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient admitted to a Danish emergency department, lung medical department or medical department
- Age >18 years
- Hospitalized <48 hours
- Positive COVID-19 test/diagnosis during the hospitalization
- Signs informed consent
Exclusion Criteria:
- If the patient uses > 5 LO2/min at time of recruitment
- Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinolinderivates
- Pregnancy
- Breastfeeding
- Neurogenic hearing loss
- Psoriasis
- Retinopathy
- Maculopathy
- Changes in vision field
- Severe liver disease other than amoebiases
- Severe gastrointestinal, neurological or haematological disorders
- eGFR < 45 ml/min/1.73m2
- Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval
- Myasthenia Gravis
- Uses Digoxin
- Glucose-6-phosphate dehydrogenase deficiency
- Porphyria
- Hypoglycemia at any time since hospitalization
- Severe mental illness which significantly impedes cooperation
- Severe linguistic problems that significantly impedes cooperation
- Treatment with sickle alkaloids
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Control
This arm will receive standard care and placebo in 15 days. Azithromycin placebo: Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1 Hydroxychloroquine placebo: Day 1-15: 200 mg x 2 |
Placebo Azithromycin
Placebo Hydroxychloroquine
|
Aktiv komparator: Intervention
This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days. Azithromycin: Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1 Hydroxychloroquine: Day 1-15: 200 mg x 2 |
Hydroksyklorokin
Azitromycin
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Days Alive and Discharged From Hospital Within 14 Days
Tidsramme: 14 days
|
14 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Dødelighet
Tidsramme: 30 dager
|
30 dager
|
|
Dødelighet
Tidsramme: 90 dager
|
90 dager
|
|
Dødelighet
Tidsramme: 365 dager
|
365 dager
|
|
Categorization of Hospitalization Status
Tidsramme: 14 days
|
The patient will be categorized into one of the following 8 categories depending on status of their hospitalization:
Only one category can be "yes". |
14 days
|
Length of Stay in ICU
Tidsramme: 14 days
|
Length of stay in intensive care unit.
|
14 days
|
Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization
Tidsramme: 14 days
|
14 days
|
|
Length of Hospitalization
Tidsramme: 14 days
|
14 days
|
|
Days Alive and Discharged From Hospital
Tidsramme: 30 days
|
30 days
|
|
Number of Readmissions (All Causes)
Tidsramme: 30 days
|
30 days
|
|
Number of Days Using Non-invasive Ventilation (NIV)
Tidsramme: 14 days
|
Number of days using non-invasive ventilation (NIV) if on NIV during hospitalization.
|
14 days
|
Change in Patient's Oxygen Partial Pressure
Tidsramme: 4 days
|
PaO2 measured in arterial puncture at baseline and 4 days.
|
4 days
|
Change in Patient's Carbondioxide Partial Pressure
Tidsramme: 4 days
|
PaCO2 measured in arterial puncture at baseline and 4 days.
|
4 days
|
Change of pH in Blood
Tidsramme: 4 days
|
pH measured in arterial puncture at baseline and 4 days.
|
4 days
|
Time for no Oxygen Supplement (or Regular Oxygen Supplement "LTOT")
Tidsramme: 14 days
|
Time for no oxygen supplement (or regular oxygen supplement "LTOT") if on oxygen during admission.
|
14 days
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Sivapalan P, Ulrik CS, Lappere TS, Eklof JV, Shaker SB, Bodtger UCS, Browatzki A, Meyer CN, Weinreich UM, Laursen CB, Biering-Sorensen T, Knop FK, Lundgren JD, Jensen JS. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
- Sivapalan P, Ulrik CS, Bojesen RD, Lapperre TS, Eklof JV, Hakansson KEJ, Browatzki A, Tidemansen C, Wilcke JT, Janner J, Gottlieb V, Meteran H, Porsbjerg C, Madsen BL, Moberg M, Pedersen L, Benfield TL, Lundgren JD, Knop FK, Biering-Sorensen T, Ghanizada M, Sonne TP, Bodtger UCS, Jensen SG, Rasmussen DB, Brondum E, Tupper OD, Sorensen SW, Alstrup G, Laursen CB, Moller UW, Sverrild A, Jensen JS. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 10;21(1):513. doi: 10.1186/s13063-020-04409-9.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- RNA-virusinfeksjoner
- Sykdomsattributter
- Coronavirus-infeksjoner
- Infeksjoner
- Smittsomme sykdommer
- Virussykdommer
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Enzymhemmere
- Antirevmatiske midler
- Antibakterielle midler
- Antiprotozoale midler
- Antiparasittiske midler
- Antimalariamidler
- Azitromycin
- Hydroksyklorokin
Andre studie-ID-numre
- KronLungesyg_COVID_19_protokol
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Virussykdommer
-
U.S. Army Medical Research and Development CommandFullført
-
ModernaTX, Inc.Aktiv, ikke rekrutterendeRespiratorisk syncytialt virusForente stater
-
Janssen Research & Development, LLCAvsluttetRespiratoriske syncytiale virusForente stater, Belgia, Canada, Ungarn, Japan, Polen
-
ModernaTX, Inc.RekrutteringRespiratorisk syncytialt virusCanada, Forente stater, Storbritannia, Puerto Rico
-
ModernaTX, Inc.Aktiv, ikke rekrutterendeRespiratorisk syncytialt virusForente stater, Panama
-
ModernaTX, Inc.Aktiv, ikke rekrutterendeRespiratorisk syncytialt virusForente stater, Spania, Taiwan, Korea, Republikken, Singapore, Canada, Belgia, Finland, Japan, Storbritannia, Chile, New Zealand, Sør-Afrika, Australia, Puerto Rico, Argentina, Costa Rica, Polen, Bangladesh, Colombia, Tyskland, Mexico, Pana...
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute...Fullført
-
Janssen Research & Development, LLCAvsluttetRespiratoriske syncytiale virusAustralia, Frankrike, Storbritannia, Belgia, Taiwan, Forente stater, Spania, Argentina, Mexico, Bulgaria, Malaysia, Japan, Sverige, Korea, Republikken, Canada, Nederland, Brasil, Tyskland, Polen
-
TakedaFullførtFlavivirus infeksjoner | Friske deltakere | Virus, Zika | Zika virus sykdomForente stater, Puerto Rico
-
ModernaTX, Inc.RekrutteringRespiratorisk syncytialt virusCanada, Storbritannia, Japan, Forente stater, Chile, Danmark, Panama, Sør-Afrika